Another CCR2 inhibitor, CCX872, was demonstrated to improve anti‐PD‐1 treatment in preclinical settings and positive results were also obtained when used in combination with the FOLFIRINOX strategy in pancreatic cancer patients.320. The gene discussed is CCR2; the disease is pancreatic neoplasm.